British Journal of Clinical Pharmacology · 2002 · 59 citations · 11 references
Life SciencesGeneticsMolecular GeneticsHuman GeneticsMedical GeneticsPharmacogeneticsPharmacogenetic TestingPharmacogenomic TestingVariant DetectionCyp2c9 GenotypingCytochrome P450 Genetic PolymorphismCytochrome P450 GenotypingPolymerase Chain Reaction (Pcr)-based DiagnosisSingle Nucleotide Polymorphism TestingVariant Allele Frequency Estimation
AIMS: The aim was to develop a fast detection method for the polymorphic alleles related to impaired CYP2C9-mediated metabolism. METHODS: CYP2C9 genotypes were identified in 118 DNA samples using real-time PCR (LightCycler) followed by melting curve analysis. All samples were re-tested by validated PCR-RFLP methodology. RESULTS: The concordance between the two methods was 100% for two variant alleles. The frequencies of CYP2C9*1 (wild type), CYP2C9*2 and CYP2C9*3 (with 95% confidence intervals) were 0.81(0.05), 0.14(0.04) and 0.05(0.03), respectively, and are similar to those observed in other Caucasian populations. CONCLUSIONS: This assay is simple and rapid and may be used for CYP2C9-genotyping in a clinical setting.
11
The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism
Theresa H. Sullivan-Klose, Burhan I. Ghanayem, Douglas A. Bell et al. · Pharmacogenetics · 1996 · 587 citations
Medicine, Genetics, Pharmacology +17
Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Daniel J. Steward, Robert L. Haining, Kirk R. Henne et al. · Pharmacogenetics · 1997 · 308 citations
Genetic analysis of the human cytochrome P450 CYP2C9 locus
Michael J. Stubbins, Lorna W. Harries, Gillian Smith et al. · Pharmacogenetics · 1996 · 303 citations
Medicine, Genetics, Pharmacology +14